Information Graphics
                in
Health Technology Assessment

       Will Stahl-Timmins
           17th May 2011
Information Graphics
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
WST PhD presentation for PenTAG 17may11
maximum
value


upper
quartile




median


lower
quartile




minimum
value
maximum
value


upper
quartile




median


lower
quartile




minimum
value
WST PhD presentation for PenTAG 17may11
PhD research intro

        A journey

  My PhD (so far)

    Opportunities
PhD research intro

        A journey

  My PhD (so far)

    Opportunities
Health Technology Assessment
Health Policy


      Medical
  Practice


                   EBM

HTA




      Scientific
  Evidence
Information Graphics
                        in
   Health Technology Assessment


 Virtual presentations of information, which use
graphical elements (eg position, colour, size, etc)
 to present scientific evidence, informing health
 policy-making in terms of recommendations for
  the adoption of specific health interventions.
Research Question



How should information graphics be designed,
  produced and used in health technology
                assessment?
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
TAR review

• 50 of 98 NICE TAR reports
  reviewed

• dated Oct 2003 - Nov 2007
• content analysis
• graphics categorised
WST PhD presentation for PenTAG 17may11
• 965 graphics used
• 965 graphics used
• graphics in every report
  but one
• 965 graphics used
• graphics in every report
  but one

• 0.20 graphics per page
• 965 graphics used
• graphics in every report
  but one

• 0.20 graphics per page
• 0.58 tables per page
1.0

• 965 graphics used          0.8


• graphics in every report   0.6
  but one
                             0.4

• 0.20 graphics per page     0.2


• 0.58 tables per page        0
                                   GRAPHICS TABLES
                                    PER PAGE   PER PAGE
WST PhD presentation for PenTAG 17may11
TIME SERIES

             CEAC                                                    LINE
THRESHOLD ANALYSIS
                                                               301




                     102 124 37 38
            OTHER

  STATE TRANSITION




                     78 41
     DECISON TREE
                                           FLOW



                     5
            OTHER
                                     124




        BAR CHART

      SCATTER PLOT
                                                        AREA
                                                  /POSITION




                     88 55 44




            OTHER
                                            187




      FOREST PLOT
            OTHER
                     331 22
                                                                            OTHER
                                                                     353
USED IN NICE-COMMISSIONED TECHNOLOGY ASSESSMENT REPORTS, 2003-2007

                                      CIRCLES REPRESENT THE NUMBER OF REPORTS THAT USED A TYPE OF GRAPHIC AT LEAST ONCE, BY REPORT SECTION




                          INTRO/               SYSTEM.     SYSTEM.              MODEL            MODEL           MODEL        CONC.                APPEN-
                          BACKG.               REVIEW      REVIEW               REVIEWS          METHODS         RESULTS                           DICES
                                               METHODS     RESULTS




LINE
            TIME SERIES       10                                                     6                10         8
                                                               8                                                                                         9

                  CEAC                                                                                           31                                             2
                                                                                 2

            THRESHOLD                                          1                     1
                                                                                                                     4
                                                               1                 1                           1       8                                         1
                OTHER     3                           1




FLOW
      STATE TRANSITION        6                            2                     8                                                                         2
                                                                                                 30              2

        DECISION TREE     1                                                                          4
                                                 1             20                    5                                                                  14
                                                                                                                                                            2
                OTHER         3                   5




AREA
                              10                                                                                 10           1
            BAR CHART                                                                2                   2                                          4
                                                                   2

         SCATTER PLOT                                          1                                                  16                                    2
                                                                                         1

/POSITION       OTHER     3
                                                                       2             1           2
                                                                                                                                                       1



OTHER
          FOREST PLOT                                      25                                                                                           7

                                                                                             1    2
                OTHER             5                                    4                                                                           4
                                                                                                                         1




                                                                                                 ALL CALCULATIONS FOR CIRCLE SIZES ARE AREA-BASED. SO,
                                                                                                 A CIRCLE REPRESENTING 50 REPORTS HAS A DIAMETER OF 10mm,
                                                                                                 AND AN AREA OF 7.9mm2. A CIRCLE REPRESENTING 25 REPORTS
                                          10      20      30               40            50      HAS AN AREA OF 3.9mm2 AND A DIAMETER OF 7.1mm.
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
NICE technical advisors
  telephone interviews - needs assessment




      • 5 interviews
      • ~30 minutes
      • gist transcribed
      • framework analysis
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, “It’s difficult
                              1989)       - because it depends on the
 -                          individual appraisal”
     selective focussing needed (Thomas, 2005)

                            Some things were thought to lead to
                            complex data included:
                              - Multiple outcome measures
                              - Many subgroups
                              - Sequential treatments
                              - Mixed treatment comparisons
                              - Many variables in SA
                              - Many disease states in model
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)

                            “In terms of [presenting a large] quantity of
                            information, then the problem is usually
                            with the clinical effectiveness, and
                            summarising that.”

                            Data must be split over several pages, or
                            slides.

                            Also sensitivity analysis of models
                            mentioned.
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
                            The most commonly mentioned type of
                            data that needed to be compared to
                            another was the ICER, the overall measure
                            of the cost-effectiveness of an intervention.

                            One interviewee noticed that it was
                            frequently necessary in committee
                            meetings to “flip backwards and forwards”
                            between slides when questions were asked
                            about the certainty of evidence.
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -                       When asked
     comparison needed (Spence 2007)      if time was limited (in any part
 -   time limited (Resnikoff, 1989) appraisal process), interviewees
                            of the
 -                          responded:
     selective focussing needed (Thomas, 2005)

                          “Time is always limited”

                          or

                          “Yes, is the short answer!”

                          All five interviewees stated that time was
                          always limited for decision-makers to
                          familiarise themselves with the necessary
                          information before an appraisal committee.
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)
• Looking for instances of:
 -   complexity (Remus, 1984; 1987)
 -   summary/overview needed (Tufte 2001)
 -   comparison needed (Spence 2007)
 -   time limited (Resnikoff, 1989)
 -   selective focussing needed (Thomas, 2005)




                            Most interviewees seemed very
                            uncomfortable about the idea.

                            “it’s really not fair, on- it’s not right to give
                            some of them extra detail.”
TAR
review                  NICE
                     interviews



                                  Methods
                                   study
             Design
            & critique




    COGS                           SOC
     test                          test
1.   Small multiple techniques including
10 information graphics                                                  Sankey diagrams for overview of
                                                                         studies in a systematic review
            The Friday Information Graphic
                                                                    2.   Two-way sensitivity analysis
                                                                         matrix / bubble chart
                        16th Oct 2009


             Link diagrams for showing
                                                                    3.   Parallel coordinates for probabilistic
            connections between search                                   sensitivity analysis
      strategies in multiple systematic reviews


                                                                    4.   Technology assessment report
                                                                         graphical overview

                                                                    5.   Sankey Markov overview

                                                                    6.   ‘Whirlpool’ display for enhancing
                                                                         tornado diagram in deterministic
                                                                         sensitivity analysis

                                                                    7.   Survival synthesis bubble chart
          Peninsula Technology   Information Graphics in
            Assessment Group     Health Technology Assessment

         www.pms.ac.uk/pentag    www.pms.ac.uk/infographics

               Noy Scott House   Will Stahl-Timmins
                 Barrack Road
               Exeter EX2 5DW
                                 wstahl-timmins@pms.ac.uk
                                 +44 (0) 1392 406 967           1
                                                                    8.   Distribution-based forest plot

                                                                    9.   Search strategy link diagram

                                                                    10. Individual patient display for
                                                                        discrete event simulation
Evaluation?
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
measurements test (experiment)

            online decision       gradually increasing
            task study            decision complexity
                                  (subgroups)
            sample: general
            internet-using        measurements:
            public - respondent   decision accuracy,
            -driven sample        time & preference




numerical presentation                graphical presentation
measurements test (experiment)

           online decision       gradually increasing
           task study            decision complexity
                                 (subgroups)
           sample: general
           internet-using        measurements:
           public - respondent   decision accuracy,
           -driven sample        time & preference


http://www.pms.ac.uk/
     infographics/
measurements test (experiment)

           online decision       gradually increasing
           task study            decision complexity
                                 (subgroups)
           sample: general
           internet-using        measurements:
           public - respondent   decision accuracy,
           -driven sample        time & preference


http://www.pms.ac.uk/
     infographics/
measurements test (experiment)

           online decision       gradually increasing
           task study            decision complexity
                                 (subgroups)
           sample: general
           internet-using        measurements:
           public - respondent   decision accuracy,
           -driven sample        time & preference




seed 1



seed 2
                                                        25+ participants...

seed 3
measurements test (experiment)

               online decision       gradually increasing
               task study            decision complexity
                                     (subgroups)
               sample: general
               internet-using        measurements:
               public - respondent   decision accuracy,
               -driven sample        time & preference




                 increasing complexity




single group             males and females         low, medium, high risk
                                                   males and females
measurements test (experiment)

  online decision       gradually increasing
  task study            decision complexity
                        (subgroups)
  sample: general
  internet-using        measurements:
  public - respondent   decision accuracy,
  -driven sample        time & preference
measurements test
    (findings)
measurements test
    (findings)

Study Duration:
36 days (15th June - 21st July 2009)
measurements test
    (findings)

Study Duration:
36 days (15th June - 21st July 2009)
244 entries were recorded during
this time.
measurements test
    (findings)

Study Duration:
36 days (15th June - 21st July 2009)
244 entries were recorded during
this time.
48 excluded as possible duplicates,
leaving 196 for the analysis
measurements test
    (findings)

Study Duration:
36 days (15th June - 21st July 2009)
244 entries were recorded during
this time.
48 excluded as possible duplicates,
leaving 196 for the analysis
99 participants received the
graphical presentation first.
97 received the numerical one first.
Randomised to receive:
                     Numerical first (N=97)          Graphical first (N=99)
      did not                                                                      did not
    complete                                                                       complete
task 1 (N=19)                                                                      task 1 (N=22)
                                         Task 1

did not complete                                                          did not complete
     task 2 (N=7)                        Task 2                           task 2 (N=7)



did not complete                                                          did not complete
     task 3 (N=3)                        Task 3                           task 3 (N=2)


did not complete                                                          did not complete
details collection
             (N=6)
                                      Details                             details collection
                                                                          (N=2)
                                     collection
did not complete                                                          did not complete
     task 4 (N=7)
                                         Task 4                           task 4 (N=2)



                                                                          did not complete
                                         Task 5                           task 5 (N=2)



did not complete                                                          did not complete
     task 6 (N=2)                        Task 6                           task 6 (N=2)



     did not give
 preference (N=2)                   Preference                            did not give
                                                                          preference (N=5)
                                    collection




         38 people gave a               25 people liked       43 people gave a
         preference for the               the displays        preference for the
         numerical display                  equally           graphical display
Average Deaths (mean)
                             Numerical - Graphical group
                                                                         7787          7787          7787
                             Graphical - Numerical group



Max. Possible Deaths 7224             7224                 7224




                                                                                                                   95% confidence
                                                                         5920
                                                                                                                    mean (g-n group)

                                                                                                                    mean (n-g group)
                                                                                       5466
                                                                                                                   95% confidence

Min. Possible Deaths 5074                                                                            5114
                                      5015

                                                           4748



                            Y1               Y2                   Y3            Y4            Y5            Y6
                            N=78             N=71                 N=69          N=65          N=63          N=61
                            N=77             N=70                 N=67          N=54          N=54          N=52
Average Times (mean)
                               Numerical - Graphical
                               Graphical - Numerical

200 seconds




                                                                     95% confidence

                                                                      mean (g-n group)

                                                                      mean (n-g group)

                                                                     95% confidence




  0 seconds


              Y1
              N=78
                       Y2
                       N=71
                              Y3
                              N=69
                                              Y4
                                               N=65
                                                       Y5
                                                       N=63
                                                              Y6
                                                              N=61
              N=77     N=70   N=67             N=54    N=54   N=52
WST PhD presentation for PenTAG 17may11
20
mins




  0
secs
        num. task

                    graph. task



                                  num. task

                                              graph. task



                                                              num. task

                                                                          graph. task
       Numerical Undecided Graphical
       Preference                                           Preference
rs = .484
p < 0.05
Average Times (mean)
                               Numerical - Graphical
                               Graphical - Numerical

200 seconds




                                                                     95% confidence

                                                                      mean (g-n group)

                                                                      mean (n-g group)

                                                                     95% confidence




  0 seconds


              Y1
              N=78
                       Y2
                       N=71
                              Y3
                              N=69
                                              Y4
                                               N=65
                                                       Y5
                                                       N=63
                                                              Y6
                                                              N=61
              N=77     N=70   N=67             N=54    N=54   N=52




               numerical presentation                                             graphical presentation
Average Times (mean)
                               Numerical - Graphical                                     “in this case, i think the
                               Graphical - Numerical

200 seconds
                                                                                         graphical plus the numerical
                                                                                         makes for more confustion.
                                                                                         one or the other is sufficient”
                                                                     95% confidence

                                                                      mean (g-n group)
                                                                                         “[the graphical presentation]
                                                                      mean (n-g group)
                                                                                         seemed more confusing -
                                                                     95% confidence      too manty differnt elements
                                                                                         to look at - visual noise”

  0 seconds                                                                              “I found the screen
              Y1       Y2     Y3              Y4       Y5     Y6                         cluttered.”
              N=78     N=71   N=69             N=65    N=63   N=61
              N=77     N=70   N=67             N=54    N=54   N=52




               numerical presentation                                             graphical presentation
Average Times (mean)
                               Numerical - Graphical                                     “in this case, i think the
                               Graphical - Numerical

200 seconds
                                                                                         graphical plus the numerical
                                                                                         makes for more confustion.
                                                                                         one or the other is sufficient”
                                                                     95% confidence

                                                                      mean (g-n group)
                                                                                         “[the graphical presentation]
                                                                      mean (n-g group)
                                                                                         seemed more confusing -
                                                                     95% confidence      too manty differnt elements
                                                                                         to look at - visual noise”

  0 seconds                                                                              “I found the screen
              Y1       Y2     Y3              Y4       Y5     Y6                         cluttered.”
              N=78     N=71   N=69             N=65    N=63   N=61
              N=77     N=70   N=67             N=54    N=54   N=52




               numerical presentation                                             graphical presentation
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
COGS (Clinical effectiveness
Overview Graphical Summary
WST PhD presentation for PenTAG 17may11
COGS test
Task-based cognitive interviewing

Speak-aloud protocol

9 expert users (HTA systematic
reviewers)

Randomised, sequencial comparison
to report

Quantitative results (time and accuracy)

Qualitative results (actions and words
of participants - framework analysis)
Randomised, crossover design


 report    TASK TASK TASK TASK     TASK TASK TASK TASK
  given
   first   1 2 3 4                 5 6 7 8               TASK TASK TASK TASK


graphic    TASK TASK TASK TASK     TASK TASK TASK TASK
                                                         9 10 11 12
  given
   first   1 2 3 4                 5 6 7 8

                                 12 tasks
Task 4: Can you tell me about selection
             bias in the Peters et al. (2007) trial please?



             COGS display                          report section

  1      4        5         8     9           2      3        6     7



        6.9%
                9.3%
                                12.0%              12.3%
                                           13.5%
                                                           16.4% 17.0%
                       17.9%

24.1%
Task 8: Of the unilateral cochlear implants
              vs non-technological support trials, which
              reported at least one significant outcome
              measure, and which measures were these?


              report section                      COGS display

  1       4         5          8     9      2      3        6     7



                                           5.4%                  5.1%
                                                  6.3%
                                                         7.9%

                 13.3%
15.0%                     15.1%
        18.2%




                                   32.4%
+&,-.*,/0.*12&
!"#$%#&$&'(#&')*#&+,-.      /00$0#1'0)2#34"#56



  345




  675

                                                 two-sample t(69) = 4.4
                                                 p < 0.001
  645




   75




   45

                  %&'()*   !"#$
task accuracy

   COGS:          74.3%
   report:        46.4%




c2 (1, N = 63) = 5.12, p = 0.024
Those given COGS first
took a mean of 99.5%
of their COGS task time
with the report.


Those given the report
first took a mean of
268.5% of their COGS
task time with the
report.

two-sample t(7) = 4.0, p = 0.005
Interview 8:

Those given COGS first              “I would say I got much more of an
                                   overview, just from looking at that
took a mean of 99.5%               graphical summary”
of their COGS task time
with the report.                   Interview 3:
                                   (pointing to graphic)
                                   “This really helps to have all of those
Those given the report             elements brought together, so you
                                   can get a more holistic view of
first took a mean of                where is it from and how big is it,
268.5% of their COGS               what’s the study design.”
task time with the
report.                            Interview 1:
                                   “I speculate that I would have had a
                                   much, much less detailed idea of the
two-sample t(7) = 4.0, p = 0.005   quality of the evidence if I’d been
                                   confronted with that [the report]
                                   first.”
stated preference for COGS
key         stated preference for report
            did not state preference during task

using
report    display 1                 using
                                    COGS
               familiar-
               isation 1
                 task 1

                 task 2

                 task 3

                 task 4
                general
              reliability 1


          display 2
               familiar-
               isation 2
                 task 5

                 task 6

                 task 7

                 task 8
                general
              reliability 2


          display 3
               familiar-
               isation 3
                 task 9

                task 10

                task 11

                task 12

                 probe



      general questions
         useful for
       this review?
         useful for
    other reviews?
     validate tasks

 interactive version
stated preference for COGS
key         stated preference for report
            did not state preference during task

using
report    display 1                 using
                                    COGS           Interview 7:
               familiar-
               isation 1
                 task 1                            “I do think [the overall quality of the
                 task 2                            evidence is] easier to see with this,
                 task 3
                                                   actually. It’s a good way of
                 task 4
                general                            presenting it.”
              reliability 1


          display 2
                                                   Interview 2:
               familiar-
               isation 2
                 task 5

                 task 6                            “again, I’m going to use the
                 task 7
                                                   graphical summary because it’s far
                 task 8
                general
              reliability 2
                                                   more useful [for this task], I think.”

          display 3
               familiar-
               isation 3
                 task 9

                task 10

                task 11

                task 12

                 probe



      general questions
         useful for
       this review?
         useful for
    other reviews?
     validate tasks

 interactive version
stated preference for COGS
key         stated preference for report
            did not state preference during task

using
report    display 1                 using
                                    COGS
               familiar-
               isation 1
                 task 1

                 task 2

                 task 3

                 task 4
                general
              reliability 1


          display 2
               familiar-
               isation 2
                 task 5

                 task 6

                 task 7

                 task 8
                general
              reliability 2


          display 3
               familiar-
               isation 3
                 task 9

                task 10

                task 11

                task 12

                 probe



      general questions
         useful for
       this review?
         useful for
    other reviews?
     validate tasks

 interactive version
stated preference for COGS
key         stated preference for report
            did not state preference during task

using
report    display 1                 using
                                    COGS           Preferred elements (N):
               familiar-
               isation 1
                 task 1                            The outcomes display (2)
                 task 2

                 task 3
                                                   The quality grid (2)
                 task 4
                general
                                                   Follow-up display (1)
              reliability 1


          display 2
                                                   Being able to compare
               familiar-                           characteristics, quality and
               isation 2
                 task 5                            outcomes together (1)
                 task 6

                 task 7
                                                   Being able to compare
                 task 8                            characteristics between studies (1)
                general
              reliability 2
                                                   The study design symbols (3)
          display 3
               familiar-                           Age display (1)
               isation 3
                 task 9

                task 10

                task 11

                task 12

                 probe



      general questions
         useful for
       this review?
         useful for
    other reviews?
     validate tasks

 interactive version
COGS test - conclusions


 Search time reduced - however, there
 was less information available overall in
 COGS.

 Gives overview

 Failed to present study designs
 successfully - revisions to key needed

 Different intervention areas will need
 different data
Design/size arrows
Height of arrow is proportional to
N (number of people tested)                   larger study                           smaller study



         pre/post design (same
     cohort is measured before
       and a er intervention).       pre-intervention
                                               N = 29
                                                          post-intervention
                                                          N = 20
                                                                              pre-intervention
                                                                                         N=7
                                                                                                  post-intervention
                                                                                                  N=2

               cross-sectional /         Intervention                             Intervention
              non-randomised                   N = 29                                    N=7

                  cohort design       Control N = 20                            Control N = 2

                                             Intervention N = 29                             Intervention N = 7

            randomised design                                                         N=9
                                             N = 49
                                               Control N = 20                                    Control N = 2

                                            Intervention N = 29
 retrospective non-randomised                                                         Intervention N = 7
            cohort study design
                                            Control N = 20                            Control N = 2



                 survey design
                                                        N = 49                                       N=9
length of follow-up
                                           0 yrs   5   10    10



        cross-sectional     Intervention
                                  N = 29
design (no follow-up)     Control N = 20


                            Intervention
                                  N = 29
       5 year follow-up
                          Control N = 20


                            Intervention
     12 year follow-up            N = 29
                          Control N = 20
follow-up                      outcome measures
         0yr   5   10   15




                                           GASP
                                           CUNY
                                            CAP
                                            CDT
                                             CID
                                            CNC
                                            CPT


                                          FMWT

                                            GSL
                                             ESP
                    Intervention N = 21

N = 43              Control N = 22
outcome measures used
                    no. of              design, size                     baseline                                study       cog func be glo
 author location   centres              & follow-up                       MMSE             sex        ages      quality




                                                                                                                             ADCS-ADL




                                                                                                                            ADCS-CGIC
                                                                                                                              ADAS-cog


                                                                                                                                  other



                                                                                                                                  other

                                                                                                                                  other
                                                                                                                                CIBIC
                                                                                                                                MMSE



                                                                                                                                 DAD
                                                                                                                                  PDS




                                                                                                                                  CDR

                                                                                                                                  QoL
                                                                                                                                   SIB




                                                                                                                                   NPI


                                                                                                                                  GDS
                                        0yr         1          2     0    10   20 30                 55 75 95

                                              Donepezil 1mg N = 42                     M         F
 Rogers &                                                                                                           Rand
                                              Donepezil 3mg N = 40                     M         F
                     ?       N = 161          Donepezil 5mg N = 39                     M         F
                                                                                                                    Char
                                                                                                                    Blind
                                                                                                                    Analy
                                                                                                                                                    1mg
                                                                                                                                                    3mg
    1996                                                                                         F
                                              Placebo N = 40                           M                                                            5mg

                                         Donepezil 5mg N = 154
                                                                                       M         F                                                  5mg
Rogers et al.                                                                                                       Rand
                                                                                       M         F                  Char                            10
                                         Donepezil 10mg N = 157                                                     Blind                           mg
 1998 (A)                    N = 473                                                                                Analy
                                                                                       M         F
                                         Placebo N = 162
                                         Donepezil 5mg N = 157
                                                                                       M         F                                                  5mg
Rogers et al.                                                                                                       Rand
                                                                                       M         F                  Char                            10
                                         Donepezil 10mg N = 158                                                                                     mg
                                                                                                                    Blind
  1998 (B)                   N = 468                                                                                Analy
                                                                                       M         F
                                         Placebo N = 153
                                         Donepezil 5mg N = 271
                                                                                       M         F                                                  5mg
 Burns et al.                                                                                                       Rand
                                                                                       M         F                  Char                            10mg
                                         Donepezil 10mg N = 273                                                     Blind
    1999                                                                                                            Analy
                             N = 818                                                   M         F
                                         Placebo N = 274

 Greenberg                               Donepezil 5mg (D)
                                                                                                                    Rand
   et al.                                      group 1 (p-D-p-p) N=30                  M         F                  Char
                                               group 2 (p-p-D-p) N=30                  M         F                  Blind
                               N = 60                                                                               Analy
    2000                                 Placebo (p)

                                         Donepezil 5mg N = 134
Homma et al.                                                                           M         F                  Rand
                                                                                                                    Char
                                                                                                                    Blind
    2000                     N = 268                                                   M         F                  Analy
                                         Placebo N = 129

                                         Donepezil 10mg N = 214
 Mohs et al.                                                                           M         F                  Rand
                                                                                                                    Char




                                                                                                                            ADCS-CGIC
                                                                                                                            ADCS-ADL
                                                                                                                    Blind




                                                                                                                            ADAS-cog
    2001                     N = 431                                                   M         F                  Analy




                                                                                                                            MMSE




                                                                                                                            CIBIC
                                         Placebo N = 217




                                                                                                                            DAD
                                                                                                                            other



                                                                                                                            other

                                                                                                                            other


                                                                                                                            CDR
                                                                                                                            GDS
                                                                                                                            PDS




                                                                                                                            QoL
                                                                                                                            NPI
                                                                                                                            SIB
                                        0yr         1          2     0    10   20 30                 55 75 95               cog   func be   glo
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
State Occupancy Charts (SOCs)
           temozolomide vs placebo
           for the treatment of newly
          diagnosed high-grade glioma




1 — State Occupancy Chart

2 — State Occupancy & Absolute Quality of Life

3 — State Occupancy & Absolute Costs Per Person

4 — Incremental State Occupancy

5 — Incremental QALYs

6 — Incremental Costs
State Occupancy Chart
                                                placebo arm                     treatment arm
                                                                                                       1
                                                 state occupancy                  state occupancy
                      week 1 surgery       0%   25%   50%     75%   100%   0%    25%   50%     75%   100% week 1
                                                                                                          week 2
            weeks 2-6 post-op recovery
                                                                                                          week 7
              weeks 7-12 radiotherapy
                                                                                                          week
    week 13+ stable/progressive/death                                                                     13
                                    week                                                                  week
                                     26                                                                   26
   is graphic shows the number
of simulated people in the six      week                                                                  week
di erent states of the model,        39                                                                   39
over the 260 one-week cycles        week                                                                  week
of the model.                        52                                                                   52

                                    week                                                                  week
During the rst week of treat-        65                                                                   65
ment, all of the people
                                    week                                                                  week
in the model were assumed            78                                                                   78
to undergo surgery, which
is represented with a seperate      week                                                                  week
state in the model.                  91                                                                   91
                                    week                                                                  week
From weeks 2-6, patients can        104                                                                   104
either be in a post-operation
recovery (treatment-free) state,    week                                                                  week
                                    117                                                                   117
or move to death in any
of these ve weeks.                  week                                                                  week
                                    130                                                                   130
In weeks 7-12, patients will        week                                                                  week
undergo radiotherapy, have          143                                                                   143
progressive disease or be dead.
                                    week                                                                  week
                                    156                                                                   156
From week 13 onwards, the
model becomes a fairly typical      week                                                                  week
three-state model, with patients    169                                                                   169
either in a stable state, having    week                                                                  week
progressive disease,                182                                                                   182
or dead.
                                    week                                                                  week
                                    195                                                                   195

        – surgery (week 1)          week                                                                  week
                                    208                                                                   208
        – post-op recovery
           (weeks 2-6)              week                                                                  week
        – radiotherapy              221                                                                   221
           (weeks 7-12)
        – stable disease            week                                                                  week
           (week 13+)               234                                                                   234
        – progressive               week                                                                  week
           disease                  247                                                                   247
        – death
                                    week                                                                  week
                                    260                                                                   260
State Occupancy & Absolute Quality of Life                                                       2
                                                 placebo arm                   treatment arm
                       week 1 surgery       0%   25%   50%   75%   100%   0%    25%   50%   75%   100% week 1
                                                                                                       week 2
             weeks 2-6 post-op recovery
                                                                                                       week 7
                weeks 7-12 radiotherapy
                                                                                                       week
    week 13+ stable/progressive/death                                                                  13
                                     week                                                              week
                                      26                                                               26
   is information graphic shows
the absolute quality of life         week                                                              week
experienced by the simulated          39                                                               39
patients in the model. e             week                                                              week
shades of grey provide a scale        52                                                               52
from black (a utility of 1 per
                                     week                                                              week
person) to white (a utility of 0      65                                                               65
per person).
                                     week                                                              week
                                      78                                                               78
   ese shades of grey are
presented in bars whose length       week                                                              week
correspond to the number              91                                                               91
of people in that state in the       week                                                              week
model during that week, as in        104                                                               104
graphic 1 — State Occupancy.
                                     week                                                              week
                                     117                                                               117
   e slowly lightening e ect in
the progressive state is caused      week                                                              week
by the gradual decomposition         130                                                               130
of utility values in this state in   week                                                              week
the model. e simulated               143                                                               143
patients experience less quality
                                     week                                                              week
of life the longer they spend in     156                                                               156
this state. e values presented
here are the average (mean) of       week                                                              week
the utility scores experienced       169                                                               169
by the cohort in that week of        week                                                              week
the model.                           182                                                               182

                                     week                                                              week
                                     195                                                               195
         utility of 1                week                                                              week
          (per person)               208                                                               208

                                     week                                                              week
                                     221                                                               221
         utility of 0.5              week                                                              week
                                     234                                                               234

                                     week                                                              week
                                     247                                                               247
         utility of 0                week                                                              week
                                     260                                                               260
State Occupancy & Absolute Costs Per Person                                                         3
                                                 placebo arm                   treatment arm
                                            0%   25%   50%   75%   100%   0%    25%   50%   75%   100%
                      week 1 surgery                                                                     week 1
                                                                                                         week 2
            weeks 2-6 post-op recovery
                                                                                                         week 7
               weeks 7-12 radiotherapy
                                                                                                         week
    week 13+ stable/progressive/death                                                                    13
                                     week                                                                week
                                      26                                                                 26
   is information graphic shows
the absolute costs incurred per      week                                                                week
person in the model, on a scale       39                                                                 39
from black (£3000 per person)        week                                                                week
to white (£0 per person).             52                                                                 52

                                     week                                                                week
   ese shades of grey are             65                                                                 65
presented in bars whose length
correspond to the number             week                                                                week
of people incurring that cost         78                                                                 78
in that state in the model, as in
                                     week                                                                week
graphic 1 — State Occupancy.          91                                                                 91

   e small dark bars appearing       week                                                                week
                                     104                                                                 104
between the progressive and
death states represent the           week                                                                week
one-o costs assigned to death        117                                                                 117
in the model. e length of
                                     week                                                                week
these bars is again proportional     130                                                                 130
to the number of people dying
during that week of the model.       week                                                                week
                                     143                                                                 143
Similar dark boxes appear            week                                                                week
between the stable and               156                                                                 156
progressive states to indicate
the higher costs assigned            week                                                                week
                                     169                                                                 169
to a patient’s rst week in the
progressive state.                   week                                                                week
                                     182                                                                 182
Costs for surgery in week
                                     week                                                                week
1 are o the scale at £5953 per       195                                                                 195
person, but this cost is identical
                                     week                                                                week
in both arms of the model.           208                                                                 208

                                     week                                                                week
                                     221                                                                 221
        £3000 per person
                                     week                                                                week
                                     234                                                                 234
        £1500 per person
                                     week                                                                week
                                     247                                                                 247
        £0 per person                week                                                                week
                                     260                                                                 260
Incremental State Occupancy                    4
                                           stable   progressive   death
                       week 1 surgery                                     week 1
                                                                          week 2
             weeks 2-6 post-op recovery
                                                                          week 7
               weeks 7-12 radiotherapy
                                                                          week
    week 13+ stable/progressive/death                                     13
                                    week                                  week
                                      26                                  26
  e di erence in state
occupancy between the two           week                                  week
arms of the model are shown           39                                  39
here.                               week                                  week
                                      52                                  52
A bar extending to the
                                    week                                  week
le shows that there were more         65                                  65
people in that state during that
                                    week                                  week
week in the placebo arm than          78                                  78
in the temozolomide arm.
Extending to the right indicates    week                                  week
more people in the temozolo-          91                                  91
mide arm.                           week                                  week
                                    104                                   104
   e length of the bars, indicat-
ing the incremental di erence       week                                  week
                                    117                                   117
between the state occupancy of
the two arms, are proprtional       week                                  week
to graphic 1: State Occupancy.      130                                   130
A 10% shi is indicated by a         week                                  week
thin vertical white line.           143                                   143
                                    week                                  week
                                    156                                   156

                                    week                                  week
                                    169                                   169
                                    week                                  week
                                    182                                   182

                                    week                                  week
                                    195                                   195
                                    week                                  week
                                    208                                   208

                                    week                                  week
                                    221                                   221
   5% shi                           week                                  week
                                    234                                   234
   10% shi
   15% shi                          week                                  week
                                    247                                   247
   20% shi
                                    week                                  week
                                    260                                   260
Incremental QALYs                       5
                                             stable   progressive   total
                       week 1 surgery                                       week 1
                                                                            week 2
             weeks 2-6 post-op recovery
                                                                            week 7
               weeks 7-12 radiotherapy
                                                                            week
    week 13+ stable/progressive/death                                       13
                                      week                                  week
                                       26                                   26
   is graphic shows the
di erences between the two            week                                  week
arms of the model in terms of          39                                   39
the quality adjusted life years       week                                  week
(QALYs) that would be                  52                                   52
experienced by a simulated
                                      week                                  week
cohort of 1000 people.                 65                                   65
                                      week                                  week
A bar extending to the le              78                                   78
shows that, during that week,
more QALYs were experienced           week                                  week
by the people in the placebo           91                                   91
arm than the temololomide             week                                  week
arm. A bar extending to the           104                                   104
right represents more QALYs
experienced in the temozolo-          week                                  week
                                      117                                   117
mide arm.
                                      week                                  week
   in vertical white lines            130                                   130
show the number of QALYs              week                                  week
that would be experienced             143                                   143
in a cohort of 1000 simulated
                                      week                                  week
patients. A bar that reaches one      156                                   156
line represents one QALY.
                                      week                                  week
   e death state is not shown,        169                                   169
as no QALYs are experienced           week                                  week
in that state, as it was assigned     182                                   182
a utility of 0.
                                      week                                  week
                                      195                                   195
   e “total” column on the far
right shows a sum of the values       week                                  week
                                      208                                   208
from the other two states.
                                      week                                  week
                                      221                                   221
     incremental QALYs                week                                  week
                                      234                                   234
         1
         2                            week                                  week
                                      247                                   247
         3
                                      week                                  week
                                      260                                   260
Incremental Costs                            6
                                           stable progressive death   total
                      week 1 surgery                                          week 1
                                                                              week 2
            weeks 2-6 post-op recovery
                                                                              week 7
               weeks 7-12 radiotherapy
                                                                              week
    week 13+ stable/progressive/death                                         13
                                    week                                      week
                                     26                                       26
   is graphic shows the
di erences in costs between        week                                       week
the two arms of the model,           39                                       39
again with a cohort of 1000        week                                       week
simulated patients.                  52                                       52

                                   week                                       week
As before, a bar extending           65                                       65
to the le shows higher costs
                                   week                                       week
in the placebo arm, and              78                                       78
a bar extending to the right
shows higher costs in              week                                       week
the temozolomide arm.                91                                       91
                                   week                                       week
   e thin vertical white lines      104                                       104
show cost thresholds in
increments of £100,000             week                                       week
                                    117                                       117
   e “total” column on the         week                                       week
far right shows a sum of the        130                                       130
values from all three states       week                                       week
of the model.                       143                                       143
                                   week                                       week
                                    156                                       156

                                   week                                       week
                                    169                                       169
                                   week                                       week
                                    182                                       182

                                   week                                       week
                                    195                                       195
                                    week                                      week
                                    208                                       208
      incremental costs
                                   week                                       week
  £100,000                          221                                       221
  £200,000
                                   week                                       week
  £300,000                          234                                       234
  £400,000
                                   week                                       week
  £500,000                          247                                       247
  £600,000                         week                                       week
                                    260                                       260
SOC test

Task-based cognitive interviewing

Probing protocol (Interviewer-led)

6 expert users (HTA modellers)

Stand-alone evaluation (no comparator)

Tasks used to assess understanding

Qualitative results (participants asked
for opinions - framework analysis)
Task 1



Q: How many people
have progressive
disease in week 52 of
the temozolomide arm
of the model?


A: 32.7%
Task 1
Task 2
Q: Where do the costs tend to come from in
each arm of the model?
Task 2
Task 6
Q: Where does the greatest difference between
the costs of the two arms lie?
Task 6
SOC test - conclusions

 Participants largely understood
 meaning of displays

 Main function is to give overview,
 adding a temporal display to existing
 methods

 Considered useful by participants

 Could be used to display SA?

 Applicability to other models - with
 many more states?
placebo arm
       0%   25%    50%     75%       100%

                                                £5.9m


                                            week 1 surgery
week
 26

week
 39
                                                  £1.6m
week
 52
                                            weeks 7-12 radiotherapy
week
 65
week
 78

week                                            £6.7m
 91
week
104
                                            weeks 2+ progressive disease
week
117
week                                             £3.1m
130

week
143                                         weeks 2+ death
week
156

week
169
week
182

week
195
week                                        chemotherapy drugs
208

week
221                                         radiotherapy
                  £3000 per person
week
234                                         hospital inpatient
                  £1500 per person
week
247
                                            hospital outpatient
week
                  £0 per person
260
Total Incremental Costs and QALYs
                                              total
                                          incremental
                                                                       total
                                                                   incremental
                                                                                         7
                                             QALYs                    costs
                      week 1 surgery                                                     week 1
                                                                                         week 2
            weeks 2-6 post-op recovery
                                                                                         week 7
              weeks 7-12 radiotherapy
                                                                                         week
    week 13+ stable/progressive/death                                                    13
                                   week                                                  week
                                     26                                                  26
   is graphic shows how            week                                                  week
adopting temozolomide                39                                                  39
treatment would a ect              week                                                  week
quality of life and costs            52                                                  52
incurred over time.
                                   week                                                  week
                                     65                                                  65
   e grey bars show the change
                                   week                                                  week
in costs and QALYs each week,        78                                                  78
and the solid black lines show
the cumulative e ects of           week                                                  week
                                     91                                                  91
adopting the treatment.
                                   week                                                  week
                                   104                                                   104
It should be noted that the
weekly values are presented        week                                                  week
on a di erent scale to the         117                                                   117
cumulative values. is              week                                                  week
is necessary for the two           130                                                   130
to be compared overlaid
                                   week                                                  week
in this manner.                    143                                                   143
                                   week                                                  week
                                   156                                                   156

                                   week                                                  week
                                   169                                                   169
                                   week                                                  week
                                   182                                                   182

                                   week                                                  week
                                   195                                                   195
                                   week                                                  week
                                   208                                                   208

                                   week                                                  week
     incremental                   221                                                   221
    costs / QALYs
                                   week                                                  week
                                   234                                                   234
       cumulative
     incremental                   week                                                  week
    costs / QALYs                  247                                                   247
                                   week                                                  week
                                   260                                                   260

                                                total QALY gain:           total cost:
                                                    223.1                  £8.1m
  ICER = £36,171 per QALY
Overall Conclusions
TAR
review                      NICE
                         interviews



                                      Methods
                                       study
             Design
            & critique




    COGS                               SOC
     test                              test
Research Question



How should information graphics be designed,
  produced and used in health technology
                assessment?
Design
Design




RESEARCH OUTPUTS
     Research Area   ECEHH
Production

1. Using standard visualisation tools in
   spreadsheet software (current situation
   – suitable for HTA professionals)

2. Developing new specialist software for
   use by HTA professionals (such as
   currently used for Forest plots)

3. Designing graphics on an individual
   basis (ie. in collaboration with trained
   information design professionals)
Use
 Likely that a combination of all three
 production methods will continue

 Depends on:

- complexity of information to be
   presented

- available resources
- available skills
- which (or whether) specialist software
   tools are developed
Production

1. Using standard visualisation tools in
   spreadsheet software (current situation
   – suitable for HTA professionals)




Suitable for simpler reports:
 - small number of trials in review
 - few subgroups, sequencial treatments
 or other complicating factors
 - simple treatment pathway for model
Production

2. Developing new specialist software for
   use by HTA professionals (such as
   currently used for Forest plots)


COGS software would be suitable for
giving overview of more complex
systematic reviews

SOC suitable for models in which time is a
key consideration

Likely to be other graphics - these would
further testing and evaluation
Production

3. Designing graphics on an individual
   basis (ie. in collaboration with trained
   information design professionals)


Suitable for the most complex reviews and
models, where:

  - different media become useable /
    dominant

  - particular information needs
    highlighting (area of world, timing of
    trials, etc)
Kessler               Illg et al.        Nikolopoulos           MED-EL                 Staller                 Manrique        Nikolopoulos          Harrison
                 et al.                                      et al.                                     et al.                  et al.             et al.             et al.




                    1997
                                          1999
                                                                   1999
                                                                                        2001
                                                                                                             2002
                                                                                                                                   2004
                                                                                                                                                        2004
                                                                                                                                                                             2005
                                                                                                                                                                                                    auth date
                                                                                                                                                                                                    ages
                                                                                                                                                                                         0 5 10 15 20




0 5 10 15 20
               N = 49
                                                                               N = 82
                                                                                                    N = 78
                                                                                                                                               N = 82
                                                                                                                                                                    N = 82




                                N = 167
                                                         N = 126
                                                                                                                         N = 182
                                                                                                                                                                                         0yr 5 10 15




0yr 5 10 15




                           Pr                       Pr                    Pr                   Pr                   Pr                    Pr                   Pr                   Pr
                           Se                       Se                    Se                   Se                   Se                    Se                   Se                   Se
                           As                       As                    As                   As                   As                    As                   As                   As
                           At                       At                    At                   At                   At                    At                   At                   At
                           Po                       Po                    Po                   Po                   Po                    Po                   Po                   Po
                                                                                                                                                                                                    design/size follow-up quality




                           Ot                       Ot                    Ot                   Ot                   Ot                    Ot                   Ot                   Ot
  1ST                                                                                                                                                                                  1ST
  2ST                                                                                                                                                                                 2 ST
  AVGN                                                                                                                                                                               AVGN
  AB                                                                                                                                                                                    AB
  BKB                                                                                                                                                                                 BKB
1992   1993   1994   1995   1996   1997   1998   1999   2000   2001   2002   2003   2004   2005
    Harrison et al.
Nikolopolous et al.
   Manrique et al.
       Staller et al.
         MED-EL
Nikolopolous et al.
          Illg et al.
      Kessler et al.
Future research
Developed graphics
- Use and monitoring
Evaluation of new graphics
- Other graphics designed for PhD
- Different designers’ work
- Different media?
Different audiences
- Public
- Medical professionals
Current work
European Centre for Environment and Human Health
WST PhD presentation for PenTAG 17may11
UK CARBON EMISSIONS                            IN 2009, THE UK’S DEPARTMENT
                                               FOR ENERGY AND CLIMATE CHANGE

2009                                           CALCULATED THAT WE EMMITTED
                                               564 TONNES OF CO2 - CARBON
                                               DIOXIDE. HERE’S HOW THAT
                8t                             BREAKS DOWN INTO DIFFERENT
                                 195t          SECTORS.
          10t

                                                                ENERGY


         18t                                                    TRANSPORT


                                                                BUSINESS


                                                                RESIDENTIAL
                                        123t

   50t
                                                                AGRICULTURE


                                                                WASTE

                           86t                                  INDUSTRIAL
                     79t


                                                                PUBLIC SECTOR
ATMOSPHERIC COLUMN                      ATMOSPHERIC SERVICES

                        SATELLITES            SERVICES AT ALL THREE ALTITUDES
                        LOW EARTH ORBIT
                        160—2000 km

                                                PLASMA AND METEORS


                        SOUNDING
                        ROCKETS
                        50—1500 km              DISPERSION OF AIR POLLUTION



       STRATOSPHERE
             10—50 km                           PROPERTIES




                        WEATHER
                        BALLOONS
                        0—40 km

                                                   UPPER AND LOWER TROPOSPHERE



  UPPER TROPOSPHERE
                        AIRCRAFT
              1—10 km   CRUISING
                        6—12 km



LOWER TROPOSPHERE
                             POWER STATIONS
             0—1 km          80—350 m



  COLUMN BASE:               WIND TURBINES
                             80—130 m
          1 km2

More Related Content

PPTX
Ntalk Presentation EWB 2011
PDF
Wst graphical web_v2
PPTX
I18n share
PDF
WST visualisation workshop intro
PPTX
Youtubeneilperkin0510 100513045248-phpapp02
PPTX
Dog island
DOCX
Ficha mat revisão_angulos
PPTX
Our trip to the zoo
Ntalk Presentation EWB 2011
Wst graphical web_v2
I18n share
WST visualisation workshop intro
Youtubeneilperkin0510 100513045248-phpapp02
Dog island
Ficha mat revisão_angulos
Our trip to the zoo

Similar to WST PhD presentation for PenTAG 17may11 (20)

PDF
股票期貨問答
PDF
Taiwan market strategy 2011 12_15_c_tw
PDF
L2322e Trs2510 4page
PDF
RT-PTN-03.5 (Company Profile Nov 2011 Linkedin)
PDF
Дарья Борисова. Лучшие практики в решении транспортных проблем
PDF
20111005 cpm-e-news
PDF
srm suite webinar
DOCX
บริษัท ไทยออยล์ จำกัด
DOCX
บริษัท ไทยออยล์ จำกัด
PPT
Basic spc class
DOCX
ธนาคารกสิกรไทย
PDF
MSc LL Katja Leszczynska 2010
PDF
Compositional and environmental factors role on compression index
PDF
กองทุนส่งเสริมป้องกันสุขภาพ53 โดย ทพ.กวี วีระเศรษฐกุล (31มีค53)
PPT
Pcb Production and Prototype Manufacturing Capabilities for Saturn Electronic...
PPT
LED MCPCB Fabrication Manufacturer
PDF
Intergalva 2009: Trends in Kettle Corrosion
DOCX
PDF
Guidelines for marine lifting operation noble denton
PDF
Guidelines for marine lifting operations
股票期貨問答
Taiwan market strategy 2011 12_15_c_tw
L2322e Trs2510 4page
RT-PTN-03.5 (Company Profile Nov 2011 Linkedin)
Дарья Борисова. Лучшие практики в решении транспортных проблем
20111005 cpm-e-news
srm suite webinar
บริษัท ไทยออยล์ จำกัด
บริษัท ไทยออยล์ จำกัด
Basic spc class
ธนาคารกสิกรไทย
MSc LL Katja Leszczynska 2010
Compositional and environmental factors role on compression index
กองทุนส่งเสริมป้องกันสุขภาพ53 โดย ทพ.กวี วีระเศรษฐกุล (31มีค53)
Pcb Production and Prototype Manufacturing Capabilities for Saturn Electronic...
LED MCPCB Fabrication Manufacturer
Intergalva 2009: Trends in Kettle Corrosion
Guidelines for marine lifting operation noble denton
Guidelines for marine lifting operations
Ad

More from Will Stahl-Timmins (13)

PDF
Farr institute - information graphics at The BMJ
PDF
Farr institute - information graphics in context
PDF
Ida oct 2014
PDF
Visualising Climate Change - Data Visualisation Workshop Intro
PDF
FoE nov 2013
PDF
Seeing is Believing
PDF
GC information graphics masterclass
PDF
Data to evidence
PDF
Wst chem21
PPT
Corner communicating climate change
PPT
Bernd Eggen - Health Impacts of Climate Change
KEY
Seeing is Believing - Information Design Conference 2012
KEY
WST UWE MA Graphic Arts group 22mar11
Farr institute - information graphics at The BMJ
Farr institute - information graphics in context
Ida oct 2014
Visualising Climate Change - Data Visualisation Workshop Intro
FoE nov 2013
Seeing is Believing
GC information graphics masterclass
Data to evidence
Wst chem21
Corner communicating climate change
Bernd Eggen - Health Impacts of Climate Change
Seeing is Believing - Information Design Conference 2012
WST UWE MA Graphic Arts group 22mar11
Ad

WST PhD presentation for PenTAG 17may11

  • 1. Information Graphics in Health Technology Assessment Will Stahl-Timmins 17th May 2011
  • 17. PhD research intro A journey My PhD (so far) Opportunities
  • 18. PhD research intro A journey My PhD (so far) Opportunities
  • 20. Health Policy Medical Practice EBM HTA Scientific Evidence
  • 21. Information Graphics in Health Technology Assessment Virtual presentations of information, which use graphical elements (eg position, colour, size, etc) to present scientific evidence, informing health policy-making in terms of recommendations for the adoption of specific health interventions.
  • 22. Research Question How should information graphics be designed, produced and used in health technology assessment?
  • 23. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 24. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 25. TAR review • 50 of 98 NICE TAR reports reviewed • dated Oct 2003 - Nov 2007 • content analysis • graphics categorised
  • 28. • 965 graphics used • graphics in every report but one
  • 29. • 965 graphics used • graphics in every report but one • 0.20 graphics per page
  • 30. • 965 graphics used • graphics in every report but one • 0.20 graphics per page • 0.58 tables per page
  • 31. 1.0 • 965 graphics used 0.8 • graphics in every report 0.6 but one 0.4 • 0.20 graphics per page 0.2 • 0.58 tables per page 0 GRAPHICS TABLES PER PAGE PER PAGE
  • 33. TIME SERIES CEAC LINE THRESHOLD ANALYSIS 301 102 124 37 38 OTHER STATE TRANSITION 78 41 DECISON TREE FLOW 5 OTHER 124 BAR CHART SCATTER PLOT AREA /POSITION 88 55 44 OTHER 187 FOREST PLOT OTHER 331 22 OTHER 353
  • 34. USED IN NICE-COMMISSIONED TECHNOLOGY ASSESSMENT REPORTS, 2003-2007 CIRCLES REPRESENT THE NUMBER OF REPORTS THAT USED A TYPE OF GRAPHIC AT LEAST ONCE, BY REPORT SECTION INTRO/ SYSTEM. SYSTEM. MODEL MODEL MODEL CONC. APPEN- BACKG. REVIEW REVIEW REVIEWS METHODS RESULTS DICES METHODS RESULTS LINE TIME SERIES 10 6 10 8 8 9 CEAC 31 2 2 THRESHOLD 1 1 4 1 1 1 8 1 OTHER 3 1 FLOW STATE TRANSITION 6 2 8 2 30 2 DECISION TREE 1 4 1 20 5 14 2 OTHER 3 5 AREA 10 10 1 BAR CHART 2 2 4 2 SCATTER PLOT 1 16 2 1 /POSITION OTHER 3 2 1 2 1 OTHER FOREST PLOT 25 7 1 2 OTHER 5 4 4 1 ALL CALCULATIONS FOR CIRCLE SIZES ARE AREA-BASED. SO, A CIRCLE REPRESENTING 50 REPORTS HAS A DIAMETER OF 10mm, AND AN AREA OF 7.9mm2. A CIRCLE REPRESENTING 25 REPORTS 10 20 30 40 50 HAS AN AREA OF 3.9mm2 AND A DIAMETER OF 7.1mm.
  • 35. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 36. NICE technical advisors telephone interviews - needs assessment • 5 interviews • ~30 minutes • gist transcribed • framework analysis
  • 37. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005)
  • 38. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005)
  • 39. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, “It’s difficult 1989) - because it depends on the - individual appraisal” selective focussing needed (Thomas, 2005) Some things were thought to lead to complex data included: - Multiple outcome measures - Many subgroups - Sequential treatments - Mixed treatment comparisons - Many variables in SA - Many disease states in model
  • 40. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005)
  • 41. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005) “In terms of [presenting a large] quantity of information, then the problem is usually with the clinical effectiveness, and summarising that.” Data must be split over several pages, or slides. Also sensitivity analysis of models mentioned.
  • 42. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005)
  • 43. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005) The most commonly mentioned type of data that needed to be compared to another was the ICER, the overall measure of the cost-effectiveness of an intervention. One interviewee noticed that it was frequently necessary in committee meetings to “flip backwards and forwards” between slides when questions were asked about the certainty of evidence.
  • 44. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005)
  • 45. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - When asked comparison needed (Spence 2007) if time was limited (in any part - time limited (Resnikoff, 1989) appraisal process), interviewees of the - responded: selective focussing needed (Thomas, 2005) “Time is always limited” or “Yes, is the short answer!” All five interviewees stated that time was always limited for decision-makers to familiarise themselves with the necessary information before an appraisal committee.
  • 46. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005)
  • 47. • Looking for instances of: - complexity (Remus, 1984; 1987) - summary/overview needed (Tufte 2001) - comparison needed (Spence 2007) - time limited (Resnikoff, 1989) - selective focussing needed (Thomas, 2005) Most interviewees seemed very uncomfortable about the idea. “it’s really not fair, on- it’s not right to give some of them extra detail.”
  • 48. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 49. 1. Small multiple techniques including 10 information graphics Sankey diagrams for overview of studies in a systematic review The Friday Information Graphic 2. Two-way sensitivity analysis matrix / bubble chart 16th Oct 2009 Link diagrams for showing 3. Parallel coordinates for probabilistic connections between search sensitivity analysis strategies in multiple systematic reviews 4. Technology assessment report graphical overview 5. Sankey Markov overview 6. ‘Whirlpool’ display for enhancing tornado diagram in deterministic sensitivity analysis 7. Survival synthesis bubble chart Peninsula Technology Information Graphics in Assessment Group Health Technology Assessment www.pms.ac.uk/pentag www.pms.ac.uk/infographics Noy Scott House Will Stahl-Timmins Barrack Road Exeter EX2 5DW [email protected] +44 (0) 1392 406 967 1 8. Distribution-based forest plot 9. Search strategy link diagram 10. Individual patient display for discrete event simulation
  • 51. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 52. measurements test (experiment) online decision gradually increasing task study decision complexity (subgroups) sample: general internet-using measurements: public - respondent decision accuracy, -driven sample time & preference numerical presentation graphical presentation
  • 53. measurements test (experiment) online decision gradually increasing task study decision complexity (subgroups) sample: general internet-using measurements: public - respondent decision accuracy, -driven sample time & preference http://www.pms.ac.uk/ infographics/
  • 54. measurements test (experiment) online decision gradually increasing task study decision complexity (subgroups) sample: general internet-using measurements: public - respondent decision accuracy, -driven sample time & preference http://www.pms.ac.uk/ infographics/
  • 55. measurements test (experiment) online decision gradually increasing task study decision complexity (subgroups) sample: general internet-using measurements: public - respondent decision accuracy, -driven sample time & preference seed 1 seed 2 25+ participants... seed 3
  • 56. measurements test (experiment) online decision gradually increasing task study decision complexity (subgroups) sample: general internet-using measurements: public - respondent decision accuracy, -driven sample time & preference increasing complexity single group males and females low, medium, high risk males and females
  • 57. measurements test (experiment) online decision gradually increasing task study decision complexity (subgroups) sample: general internet-using measurements: public - respondent decision accuracy, -driven sample time & preference
  • 58. measurements test (findings)
  • 59. measurements test (findings) Study Duration: 36 days (15th June - 21st July 2009)
  • 60. measurements test (findings) Study Duration: 36 days (15th June - 21st July 2009) 244 entries were recorded during this time.
  • 61. measurements test (findings) Study Duration: 36 days (15th June - 21st July 2009) 244 entries were recorded during this time. 48 excluded as possible duplicates, leaving 196 for the analysis
  • 62. measurements test (findings) Study Duration: 36 days (15th June - 21st July 2009) 244 entries were recorded during this time. 48 excluded as possible duplicates, leaving 196 for the analysis 99 participants received the graphical presentation first. 97 received the numerical one first.
  • 63. Randomised to receive: Numerical first (N=97) Graphical first (N=99) did not did not complete complete task 1 (N=19) task 1 (N=22) Task 1 did not complete did not complete task 2 (N=7) Task 2 task 2 (N=7) did not complete did not complete task 3 (N=3) Task 3 task 3 (N=2) did not complete did not complete details collection (N=6) Details details collection (N=2) collection did not complete did not complete task 4 (N=7) Task 4 task 4 (N=2) did not complete Task 5 task 5 (N=2) did not complete did not complete task 6 (N=2) Task 6 task 6 (N=2) did not give preference (N=2) Preference did not give preference (N=5) collection 38 people gave a 25 people liked 43 people gave a preference for the the displays preference for the numerical display equally graphical display
  • 64. Average Deaths (mean) Numerical - Graphical group 7787 7787 7787 Graphical - Numerical group Max. Possible Deaths 7224 7224 7224 95% confidence 5920 mean (g-n group) mean (n-g group) 5466 95% confidence Min. Possible Deaths 5074 5114 5015 4748 Y1 Y2 Y3 Y4 Y5 Y6 N=78 N=71 N=69 N=65 N=63 N=61 N=77 N=70 N=67 N=54 N=54 N=52
  • 65. Average Times (mean) Numerical - Graphical Graphical - Numerical 200 seconds 95% confidence mean (g-n group) mean (n-g group) 95% confidence 0 seconds Y1 N=78 Y2 N=71 Y3 N=69 Y4 N=65 Y5 N=63 Y6 N=61 N=77 N=70 N=67 N=54 N=54 N=52
  • 67. 20 mins 0 secs num. task graph. task num. task graph. task num. task graph. task Numerical Undecided Graphical Preference Preference
  • 68. rs = .484 p < 0.05
  • 69. Average Times (mean) Numerical - Graphical Graphical - Numerical 200 seconds 95% confidence mean (g-n group) mean (n-g group) 95% confidence 0 seconds Y1 N=78 Y2 N=71 Y3 N=69 Y4 N=65 Y5 N=63 Y6 N=61 N=77 N=70 N=67 N=54 N=54 N=52 numerical presentation graphical presentation
  • 70. Average Times (mean) Numerical - Graphical “in this case, i think the Graphical - Numerical 200 seconds graphical plus the numerical makes for more confustion. one or the other is sufficient” 95% confidence mean (g-n group) “[the graphical presentation] mean (n-g group) seemed more confusing - 95% confidence too manty differnt elements to look at - visual noise” 0 seconds “I found the screen Y1 Y2 Y3 Y4 Y5 Y6 cluttered.” N=78 N=71 N=69 N=65 N=63 N=61 N=77 N=70 N=67 N=54 N=54 N=52 numerical presentation graphical presentation
  • 71. Average Times (mean) Numerical - Graphical “in this case, i think the Graphical - Numerical 200 seconds graphical plus the numerical makes for more confustion. one or the other is sufficient” 95% confidence mean (g-n group) “[the graphical presentation] mean (n-g group) seemed more confusing - 95% confidence too manty differnt elements to look at - visual noise” 0 seconds “I found the screen Y1 Y2 Y3 Y4 Y5 Y6 cluttered.” N=78 N=71 N=69 N=65 N=63 N=61 N=77 N=70 N=67 N=54 N=54 N=52 numerical presentation graphical presentation
  • 72. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 75. COGS test Task-based cognitive interviewing Speak-aloud protocol 9 expert users (HTA systematic reviewers) Randomised, sequencial comparison to report Quantitative results (time and accuracy) Qualitative results (actions and words of participants - framework analysis)
  • 76. Randomised, crossover design report TASK TASK TASK TASK TASK TASK TASK TASK given first 1 2 3 4 5 6 7 8 TASK TASK TASK TASK graphic TASK TASK TASK TASK TASK TASK TASK TASK 9 10 11 12 given first 1 2 3 4 5 6 7 8 12 tasks
  • 77. Task 4: Can you tell me about selection bias in the Peters et al. (2007) trial please? COGS display report section 1 4 5 8 9 2 3 6 7 6.9% 9.3% 12.0% 12.3% 13.5% 16.4% 17.0% 17.9% 24.1%
  • 78. Task 8: Of the unilateral cochlear implants vs non-technological support trials, which reported at least one significant outcome measure, and which measures were these? report section COGS display 1 4 5 8 9 2 3 6 7 5.4% 5.1% 6.3% 7.9% 13.3% 15.0% 15.1% 18.2% 32.4%
  • 79. +&,-.*,/0.*12& !"#$%#&$&'(#&')*#&+,-. /00$0#1'0)2#34"#56 345 675 two-sample t(69) = 4.4 p < 0.001 645 75 45 %&'()* !"#$
  • 80. task accuracy COGS: 74.3% report: 46.4% c2 (1, N = 63) = 5.12, p = 0.024
  • 81. Those given COGS first took a mean of 99.5% of their COGS task time with the report. Those given the report first took a mean of 268.5% of their COGS task time with the report. two-sample t(7) = 4.0, p = 0.005
  • 82. Interview 8: Those given COGS first “I would say I got much more of an overview, just from looking at that took a mean of 99.5% graphical summary” of their COGS task time with the report. Interview 3: (pointing to graphic) “This really helps to have all of those Those given the report elements brought together, so you can get a more holistic view of first took a mean of where is it from and how big is it, 268.5% of their COGS what’s the study design.” task time with the report. Interview 1: “I speculate that I would have had a much, much less detailed idea of the two-sample t(7) = 4.0, p = 0.005 quality of the evidence if I’d been confronted with that [the report] first.”
  • 83. stated preference for COGS key stated preference for report did not state preference during task using report display 1 using COGS familiar- isation 1 task 1 task 2 task 3 task 4 general reliability 1 display 2 familiar- isation 2 task 5 task 6 task 7 task 8 general reliability 2 display 3 familiar- isation 3 task 9 task 10 task 11 task 12 probe general questions useful for this review? useful for other reviews? validate tasks interactive version
  • 84. stated preference for COGS key stated preference for report did not state preference during task using report display 1 using COGS Interview 7: familiar- isation 1 task 1 “I do think [the overall quality of the task 2 evidence is] easier to see with this, task 3 actually. It’s a good way of task 4 general presenting it.” reliability 1 display 2 Interview 2: familiar- isation 2 task 5 task 6 “again, I’m going to use the task 7 graphical summary because it’s far task 8 general reliability 2 more useful [for this task], I think.” display 3 familiar- isation 3 task 9 task 10 task 11 task 12 probe general questions useful for this review? useful for other reviews? validate tasks interactive version
  • 85. stated preference for COGS key stated preference for report did not state preference during task using report display 1 using COGS familiar- isation 1 task 1 task 2 task 3 task 4 general reliability 1 display 2 familiar- isation 2 task 5 task 6 task 7 task 8 general reliability 2 display 3 familiar- isation 3 task 9 task 10 task 11 task 12 probe general questions useful for this review? useful for other reviews? validate tasks interactive version
  • 86. stated preference for COGS key stated preference for report did not state preference during task using report display 1 using COGS Preferred elements (N): familiar- isation 1 task 1 The outcomes display (2) task 2 task 3 The quality grid (2) task 4 general Follow-up display (1) reliability 1 display 2 Being able to compare familiar- characteristics, quality and isation 2 task 5 outcomes together (1) task 6 task 7 Being able to compare task 8 characteristics between studies (1) general reliability 2 The study design symbols (3) display 3 familiar- Age display (1) isation 3 task 9 task 10 task 11 task 12 probe general questions useful for this review? useful for other reviews? validate tasks interactive version
  • 87. COGS test - conclusions Search time reduced - however, there was less information available overall in COGS. Gives overview Failed to present study designs successfully - revisions to key needed Different intervention areas will need different data
  • 88. Design/size arrows Height of arrow is proportional to N (number of people tested) larger study smaller study pre/post design (same cohort is measured before and a er intervention). pre-intervention N = 29 post-intervention N = 20 pre-intervention N=7 post-intervention N=2 cross-sectional / Intervention Intervention non-randomised N = 29 N=7 cohort design Control N = 20 Control N = 2 Intervention N = 29 Intervention N = 7 randomised design N=9 N = 49 Control N = 20 Control N = 2 Intervention N = 29 retrospective non-randomised Intervention N = 7 cohort study design Control N = 20 Control N = 2 survey design N = 49 N=9
  • 89. length of follow-up 0 yrs 5 10 10 cross-sectional Intervention N = 29 design (no follow-up) Control N = 20 Intervention N = 29 5 year follow-up Control N = 20 Intervention 12 year follow-up N = 29 Control N = 20
  • 90. follow-up outcome measures 0yr 5 10 15 GASP CUNY CAP CDT CID CNC CPT FMWT GSL ESP Intervention N = 21 N = 43 Control N = 22
  • 91. outcome measures used no. of design, size baseline study cog func be glo author location centres & follow-up MMSE sex ages quality ADCS-ADL ADCS-CGIC ADAS-cog other other other CIBIC MMSE DAD PDS CDR QoL SIB NPI GDS 0yr 1 2 0 10 20 30 55 75 95 Donepezil 1mg N = 42 M F Rogers & Rand Donepezil 3mg N = 40 M F ? N = 161 Donepezil 5mg N = 39 M F Char Blind Analy 1mg 3mg 1996 F Placebo N = 40 M 5mg Donepezil 5mg N = 154 M F 5mg Rogers et al. Rand M F Char 10 Donepezil 10mg N = 157 Blind mg 1998 (A) N = 473 Analy M F Placebo N = 162 Donepezil 5mg N = 157 M F 5mg Rogers et al. Rand M F Char 10 Donepezil 10mg N = 158 mg Blind 1998 (B) N = 468 Analy M F Placebo N = 153 Donepezil 5mg N = 271 M F 5mg Burns et al. Rand M F Char 10mg Donepezil 10mg N = 273 Blind 1999 Analy N = 818 M F Placebo N = 274 Greenberg Donepezil 5mg (D) Rand et al. group 1 (p-D-p-p) N=30 M F Char group 2 (p-p-D-p) N=30 M F Blind N = 60 Analy 2000 Placebo (p) Donepezil 5mg N = 134 Homma et al. M F Rand Char Blind 2000 N = 268 M F Analy Placebo N = 129 Donepezil 10mg N = 214 Mohs et al. M F Rand Char ADCS-CGIC ADCS-ADL Blind ADAS-cog 2001 N = 431 M F Analy MMSE CIBIC Placebo N = 217 DAD other other other CDR GDS PDS QoL NPI SIB 0yr 1 2 0 10 20 30 55 75 95 cog func be glo
  • 92. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 93. State Occupancy Charts (SOCs) temozolomide vs placebo for the treatment of newly diagnosed high-grade glioma 1 — State Occupancy Chart 2 — State Occupancy & Absolute Quality of Life 3 — State Occupancy & Absolute Costs Per Person 4 — Incremental State Occupancy 5 — Incremental QALYs 6 — Incremental Costs
  • 94. State Occupancy Chart placebo arm treatment arm 1 state occupancy state occupancy week 1 surgery 0% 25% 50% 75% 100% 0% 25% 50% 75% 100% week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 is graphic shows the number of simulated people in the six week week di erent states of the model, 39 39 over the 260 one-week cycles week week of the model. 52 52 week week During the rst week of treat- 65 65 ment, all of the people week week in the model were assumed 78 78 to undergo surgery, which is represented with a seperate week week state in the model. 91 91 week week From weeks 2-6, patients can 104 104 either be in a post-operation recovery (treatment-free) state, week week 117 117 or move to death in any of these ve weeks. week week 130 130 In weeks 7-12, patients will week week undergo radiotherapy, have 143 143 progressive disease or be dead. week week 156 156 From week 13 onwards, the model becomes a fairly typical week week three-state model, with patients 169 169 either in a stable state, having week week progressive disease, 182 182 or dead. week week 195 195 – surgery (week 1) week week 208 208 – post-op recovery (weeks 2-6) week week – radiotherapy 221 221 (weeks 7-12) – stable disease week week (week 13+) 234 234 – progressive week week disease 247 247 – death week week 260 260
  • 95. State Occupancy & Absolute Quality of Life 2 placebo arm treatment arm week 1 surgery 0% 25% 50% 75% 100% 0% 25% 50% 75% 100% week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 is information graphic shows the absolute quality of life week week experienced by the simulated 39 39 patients in the model. e week week shades of grey provide a scale 52 52 from black (a utility of 1 per week week person) to white (a utility of 0 65 65 per person). week week 78 78 ese shades of grey are presented in bars whose length week week correspond to the number 91 91 of people in that state in the week week model during that week, as in 104 104 graphic 1 — State Occupancy. week week 117 117 e slowly lightening e ect in the progressive state is caused week week by the gradual decomposition 130 130 of utility values in this state in week week the model. e simulated 143 143 patients experience less quality week week of life the longer they spend in 156 156 this state. e values presented here are the average (mean) of week week the utility scores experienced 169 169 by the cohort in that week of week week the model. 182 182 week week 195 195 utility of 1 week week (per person) 208 208 week week 221 221 utility of 0.5 week week 234 234 week week 247 247 utility of 0 week week 260 260
  • 96. State Occupancy & Absolute Costs Per Person 3 placebo arm treatment arm 0% 25% 50% 75% 100% 0% 25% 50% 75% 100% week 1 surgery week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 is information graphic shows the absolute costs incurred per week week person in the model, on a scale 39 39 from black (£3000 per person) week week to white (£0 per person). 52 52 week week ese shades of grey are 65 65 presented in bars whose length correspond to the number week week of people incurring that cost 78 78 in that state in the model, as in week week graphic 1 — State Occupancy. 91 91 e small dark bars appearing week week 104 104 between the progressive and death states represent the week week one-o costs assigned to death 117 117 in the model. e length of week week these bars is again proportional 130 130 to the number of people dying during that week of the model. week week 143 143 Similar dark boxes appear week week between the stable and 156 156 progressive states to indicate the higher costs assigned week week 169 169 to a patient’s rst week in the progressive state. week week 182 182 Costs for surgery in week week week 1 are o the scale at £5953 per 195 195 person, but this cost is identical week week in both arms of the model. 208 208 week week 221 221 £3000 per person week week 234 234 £1500 per person week week 247 247 £0 per person week week 260 260
  • 97. Incremental State Occupancy 4 stable progressive death week 1 surgery week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 e di erence in state occupancy between the two week week arms of the model are shown 39 39 here. week week 52 52 A bar extending to the week week le shows that there were more 65 65 people in that state during that week week week in the placebo arm than 78 78 in the temozolomide arm. Extending to the right indicates week week more people in the temozolo- 91 91 mide arm. week week 104 104 e length of the bars, indicat- ing the incremental di erence week week 117 117 between the state occupancy of the two arms, are proprtional week week to graphic 1: State Occupancy. 130 130 A 10% shi is indicated by a week week thin vertical white line. 143 143 week week 156 156 week week 169 169 week week 182 182 week week 195 195 week week 208 208 week week 221 221 5% shi week week 234 234 10% shi 15% shi week week 247 247 20% shi week week 260 260
  • 98. Incremental QALYs 5 stable progressive total week 1 surgery week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 is graphic shows the di erences between the two week week arms of the model in terms of 39 39 the quality adjusted life years week week (QALYs) that would be 52 52 experienced by a simulated week week cohort of 1000 people. 65 65 week week A bar extending to the le 78 78 shows that, during that week, more QALYs were experienced week week by the people in the placebo 91 91 arm than the temololomide week week arm. A bar extending to the 104 104 right represents more QALYs experienced in the temozolo- week week 117 117 mide arm. week week in vertical white lines 130 130 show the number of QALYs week week that would be experienced 143 143 in a cohort of 1000 simulated week week patients. A bar that reaches one 156 156 line represents one QALY. week week e death state is not shown, 169 169 as no QALYs are experienced week week in that state, as it was assigned 182 182 a utility of 0. week week 195 195 e “total” column on the far right shows a sum of the values week week 208 208 from the other two states. week week 221 221 incremental QALYs week week 234 234 1 2 week week 247 247 3 week week 260 260
  • 99. Incremental Costs 6 stable progressive death total week 1 surgery week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 is graphic shows the di erences in costs between week week the two arms of the model, 39 39 again with a cohort of 1000 week week simulated patients. 52 52 week week As before, a bar extending 65 65 to the le shows higher costs week week in the placebo arm, and 78 78 a bar extending to the right shows higher costs in week week the temozolomide arm. 91 91 week week e thin vertical white lines 104 104 show cost thresholds in increments of £100,000 week week 117 117 e “total” column on the week week far right shows a sum of the 130 130 values from all three states week week of the model. 143 143 week week 156 156 week week 169 169 week week 182 182 week week 195 195 week week 208 208 incremental costs week week £100,000 221 221 £200,000 week week £300,000 234 234 £400,000 week week £500,000 247 247 £600,000 week week 260 260
  • 100. SOC test Task-based cognitive interviewing Probing protocol (Interviewer-led) 6 expert users (HTA modellers) Stand-alone evaluation (no comparator) Tasks used to assess understanding Qualitative results (participants asked for opinions - framework analysis)
  • 101. Task 1 Q: How many people have progressive disease in week 52 of the temozolomide arm of the model? A: 32.7%
  • 102. Task 1
  • 103. Task 2 Q: Where do the costs tend to come from in each arm of the model?
  • 104. Task 2
  • 105. Task 6 Q: Where does the greatest difference between the costs of the two arms lie?
  • 106. Task 6
  • 107. SOC test - conclusions Participants largely understood meaning of displays Main function is to give overview, adding a temporal display to existing methods Considered useful by participants Could be used to display SA? Applicability to other models - with many more states?
  • 108. placebo arm 0% 25% 50% 75% 100% £5.9m week 1 surgery week 26 week 39 £1.6m week 52 weeks 7-12 radiotherapy week 65 week 78 week £6.7m 91 week 104 weeks 2+ progressive disease week 117 week £3.1m 130 week 143 weeks 2+ death week 156 week 169 week 182 week 195 week chemotherapy drugs 208 week 221 radiotherapy £3000 per person week 234 hospital inpatient £1500 per person week 247 hospital outpatient week £0 per person 260
  • 109. Total Incremental Costs and QALYs total incremental total incremental 7 QALYs costs week 1 surgery week 1 week 2 weeks 2-6 post-op recovery week 7 weeks 7-12 radiotherapy week week 13+ stable/progressive/death 13 week week 26 26 is graphic shows how week week adopting temozolomide 39 39 treatment would a ect week week quality of life and costs 52 52 incurred over time. week week 65 65 e grey bars show the change week week in costs and QALYs each week, 78 78 and the solid black lines show the cumulative e ects of week week 91 91 adopting the treatment. week week 104 104 It should be noted that the weekly values are presented week week on a di erent scale to the 117 117 cumulative values. is week week is necessary for the two 130 130 to be compared overlaid week week in this manner. 143 143 week week 156 156 week week 169 169 week week 182 182 week week 195 195 week week 208 208 week week incremental 221 221 costs / QALYs week week 234 234 cumulative incremental week week costs / QALYs 247 247 week week 260 260 total QALY gain: total cost: 223.1 £8.1m ICER = £36,171 per QALY
  • 111. TAR review NICE interviews Methods study Design & critique COGS SOC test test
  • 112. Research Question How should information graphics be designed, produced and used in health technology assessment?
  • 113. Design
  • 114. Design RESEARCH OUTPUTS Research Area ECEHH
  • 115. Production 1. Using standard visualisation tools in spreadsheet software (current situation – suitable for HTA professionals) 2. Developing new specialist software for use by HTA professionals (such as currently used for Forest plots) 3. Designing graphics on an individual basis (ie. in collaboration with trained information design professionals)
  • 116. Use Likely that a combination of all three production methods will continue Depends on: - complexity of information to be presented - available resources - available skills - which (or whether) specialist software tools are developed
  • 117. Production 1. Using standard visualisation tools in spreadsheet software (current situation – suitable for HTA professionals) Suitable for simpler reports: - small number of trials in review - few subgroups, sequencial treatments or other complicating factors - simple treatment pathway for model
  • 118. Production 2. Developing new specialist software for use by HTA professionals (such as currently used for Forest plots) COGS software would be suitable for giving overview of more complex systematic reviews SOC suitable for models in which time is a key consideration Likely to be other graphics - these would further testing and evaluation
  • 119. Production 3. Designing graphics on an individual basis (ie. in collaboration with trained information design professionals) Suitable for the most complex reviews and models, where: - different media become useable / dominant - particular information needs highlighting (area of world, timing of trials, etc)
  • 120. Kessler Illg et al. Nikolopoulos MED-EL Staller Manrique Nikolopoulos Harrison et al. et al. et al. et al. et al. et al. 1997 1999 1999 2001 2002 2004 2004 2005 auth date ages 0 5 10 15 20 0 5 10 15 20 N = 49 N = 82 N = 78 N = 82 N = 82 N = 167 N = 126 N = 182 0yr 5 10 15 0yr 5 10 15 Pr Pr Pr Pr Pr Pr Pr Pr Se Se Se Se Se Se Se Se As As As As As As As As At At At At At At At At Po Po Po Po Po Po Po Po design/size follow-up quality Ot Ot Ot Ot Ot Ot Ot Ot 1ST 1ST 2ST 2 ST AVGN AVGN AB AB BKB BKB
  • 121. 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Harrison et al. Nikolopolous et al. Manrique et al. Staller et al. MED-EL Nikolopolous et al. Illg et al. Kessler et al.
  • 122. Future research Developed graphics - Use and monitoring Evaluation of new graphics - Other graphics designed for PhD - Different designers’ work - Different media? Different audiences - Public - Medical professionals
  • 124. European Centre for Environment and Human Health
  • 126. UK CARBON EMISSIONS IN 2009, THE UK’S DEPARTMENT FOR ENERGY AND CLIMATE CHANGE 2009 CALCULATED THAT WE EMMITTED 564 TONNES OF CO2 - CARBON DIOXIDE. HERE’S HOW THAT 8t BREAKS DOWN INTO DIFFERENT 195t SECTORS. 10t ENERGY 18t TRANSPORT BUSINESS RESIDENTIAL 123t 50t AGRICULTURE WASTE 86t INDUSTRIAL 79t PUBLIC SECTOR
  • 127. ATMOSPHERIC COLUMN ATMOSPHERIC SERVICES SATELLITES SERVICES AT ALL THREE ALTITUDES LOW EARTH ORBIT 160—2000 km PLASMA AND METEORS SOUNDING ROCKETS 50—1500 km DISPERSION OF AIR POLLUTION STRATOSPHERE 10—50 km PROPERTIES WEATHER BALLOONS 0—40 km UPPER AND LOWER TROPOSPHERE UPPER TROPOSPHERE AIRCRAFT 1—10 km CRUISING 6—12 km LOWER TROPOSPHERE POWER STATIONS 0—1 km 80—350 m COLUMN BASE: WIND TURBINES 80—130 m 1 km2